Oral TIX100 protects against obesity-associated glucose intolerance and diet-induced adiposity.

ABSTRACT:

Aims

Glucagon-like peptide 1 receptor agonists and dual agonists have changed the treatment landscape of obesity and type 2 diabetes (T2D), but significant limitations have emerged due to their gastrointestinal side effects, loss of lean mass, and necessity for ongoing subcutaneous injections. Our objective was, therefore, to test a novel small molecule as a different and potentially better tolerated oral medications to improve obesity-associated impairment in glucose homeostasis.

Materials and methods

High-fat diet (HFD)-fed mice or severely obese, leptin-deficient ob/ob mice were randomly assigned to serve as controls or receive oral TIX100, a novel thioredoxin-interacting protein (TXNIP) inhibitor just approved by the FDA as an investigational new drug for type 1 diabetes

SUBMITTER: Jo S 

PROVIDER: S-EPMC11885086 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature